**Supplementary Appendix 1: Search strategies**

|  |
| --- |
| Supplemental Table 1 | Search strategy |
| Medline search strategy |
| (Inflammatory Bowel Disease[Mesh] or Crohn disease[tw] or Crohn Disease[Mesh] or Crohn disease[tw] or Crohn's Enteritis\*[tw] or Ulcerative colitis\*[tw] or Crohn's Disease[tw] or Crohns Disease[tw] or Ileocolitis\*[tw] or Granulomatous Colitis\*[tw] or Terminal Ileitis[tw])  AND  (Coronavirus[Mesh] or Coronavirus[tw] or COVID-19[Mesh] or COVID-19[tw] or SARS-COV-2[Mesh] or SARS-COV-2[tw] or severe[tw] or [hospitalization[tw])  AND  ("Biologics"[Mesh] or Biologic\*[tw] or Biopharmaceutical\*[tw] or Biological Drug\*[tw] or Biological\*[tw] or Biologic Medicine\*[tw] or Biologic Pharmaceutical\*[tw] or Biologic Drug\*[tw] or Biological Medicine[tw] or “Monoclonal Antibodies”[Mesh] or Monoclonal Antibody\*[tw] or anti-TNF[tw] or “Tumor Necrosis Factor alpha"[Mesh] or Tumor Necrosis Factor alpha[tw]) |
| Embase search strategy |
| (Crohn disease.tw. or Crohn's Enteritis.tw. or Regional Enteritis.tw. or Inflammatory Bowel Disease.tw. or Ileocolitis.tw. or Granulomatous Colitis.tw. or Terminal Ileitis.tw. or Regional Ileitides.tw. or Regional Ileitis.tw.)  AND  (Coronavirus.tw. or COVID-19.tw. or SARS-COV-2.tw. OR severe.tw. OR hospitalization.tw. OR mortality.tw.)  AND  (Biologic\*.tw. or Biopharmaceutical\*.tw. or Biological Drug\*.tw. or Biological\*.tw. or Biologic Medicine\*.tw. or Biologic Pharmaceutical\*.tw. or Biologic Drug\*.tw. or Biological Medicine.tw. or Monoclonal Antibody\*.tw. or adalimumab.tw. or certolizumab.tw. or infliximab.tw. or ustekinumab.tw or vedolizumab.tw. or natalizumab.tw. or Risankizumab.tw) |

**Table 2: Quality Assessment**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Selection | | | Comparability | Outcome | | |  |
| Study | **Representativeness of sample (maximum: one star)** | **Sample size (maximum: one star)** | **Assessment of the exposure (maximum: one star)** | **Comparability of cohorts on the basis of the design or analysis (maximum: 2 stars)** | **Assessment of the outcome (maximum: one star)** | **Was follow up long enough? (maximum: one star)** | **Adequacy of follow up cohorts (maximum: one star)** | **Total score (maximum: 8 stars)** |
| Allocca et al | \* |  | \* | \* | \* |  |  | \*\*\*\* (4) |
| Annapureddy et al | \* | \* | \* | \*\* | \* |  |  | \*\*\*\*\*\* (6) |
| Attauabi et al | \* | \* |  | \*\* | \* |  |  | \*\*\*\*\* (5) |
| Axerlrad et al |  | \* | \* | \* | \* |  |  | \*\*\*\* (4) |
| Bezzio et al | \* | \* |  | \*\* | \* |  |  | \*\*\*\*\* (5) |
| Bezzio et al (2) | \* | \* |  |  | \* | \* |  | \*\*\*\* (4) |
| Burke et al | \* | \* |  | \* | \* |  |  | \*\*\*\* (4) |
| Conley et al | \* | \* | \* |  | \* |  |  | \*\*\*\* (4) |
| Derikx et al | \* | \* |  |  | \* |  |  | \*\*\*\* (4) |
| Gubatan et al | \* | \* | \* | \*\* | \* |  |  | \*\*\*\*\*\* (6) |
| Kennedy et al | \* | \* |  | \* | \* |  |  | \*\*\*\* (4) |
| Khan et al | \* | \* | \* | \* |  | \* |  | \*\*\*\*\*(5) |
| Lamp et al | \* | \* | \* | \* |  |  |  | \*\*\*\* (4) |
| Lukin et al | \* |  | \* | \* | \* |  | \* | \*\*\*\*\* (5) |
| Rizzello et al | \* | \* | \* | \*\* | \* |  |  | \*\*\*\*\*\*(6) |
| Taxonera et al | \* | \* |  | \*\* | \* |  |  | \*\*\*\*\* (5) |
| Vadan et al | \* | \* | \* |  | \* |  |  | \*\*\*\* (4) |

**Table 3: Risk of Bias**

|  |  |
| --- | --- |
| Study | Risk of bias |
| Allocca et al | Low |
| Annapureddy et al | Low |
| Attauabi et al | Low |
| Axerlrad et al | Low |
| Bezzio et al | Low |
| Bezzio et al (2) | Low |
| Burke et al | Low |
| Conley et al | Low |
| Derikx et al | Moderate |
| Gubatan et al | Low |
| Kennedy et al | Low |
| Khan et al | Low |
| Lamp et al | Low |
| Lukin et al | Low |
| Rizzello et al | Low |
| SECURE-IBD | Moderate |
| Taxonera et al | Low |
| Vadan et al | Low |